19th European Haematology Association (EHA) Congress

Prof Lawler talks to ecancertv at EHA 2014 about the disparities in cancer care worldwide - and the steps being taken to tackle them, such as the European Cancer Patient Bill of Rights.

Prof Lawler talks to ecancertv at EHA 2014 about personalised medicine and ways in which access to innovative treatments can be universalised across different European health systems through better regulation to tackle disparities.

Dr Gökbuget talks to ecancertv at EHA 2014 about the use of antibody treatments in acute lymphoblastic leukaemia.

Prof Martinelli talks to ecancertv at EHA 2014 about the use of novel targets in acute myeloid leukaemia.

Professor Foà talks to ecancertv at EHA 2014 about advances in CLL, with a particular reference to biomarkers and the difference they've made to diagnostics.

Prof Vannucchi talks to ecancertv at EHA 2014 about the RESPONSE trial of ruxolitinib, which suggests early promise for patients with polycythaemia vera.

Dr Campo talks to ecancertv at EHA 2014 about the genetics of CLL, with specific reference to ibrutinib and the RESONATE trial.

Prof Stewart talks to ecancertv at EHA 2014 about his work comparing the use of lenalidomide and thalidomide in elderly patients with multiple myeloma. The study found little difference between the two. A higher quality of life was reported with lenalidomide, but thalidomide is more cost-effective.

Dr Mazzarella talks to ecancertv at EHA 2014 about the relationship between metabolism and cancer growth, with a particular focus on the link between obesity and acute promyelocytic leukaemia.

Prof Hermine talks to ecancertv at EHA 2014 about new possible treatment options for thalassemia patients.

Prof Sonneveld provides ecancertv with an overview of the important issues being discussed at EHA 2014 in haematological cancer, with particular reference to novel agents such as the use of ibrutinib in CLL.

Prof Harrison talks to ecancertv at EHA 2014 about the Philadelphia chromosome and the role it plays in triggering chronic myeloid leukaemia (CML).

Dr Grainger talks to ecancertv at EHA 2014 about the use of eltrombopag in children to reduce bleeding and improve quality of life in immune thrombocytopenic purpura (ITP). Significant improvements were seen vis-à-vis placebo.

Dr Mazzarella talks to ecancertv at EHA 2014 about the use of retinoic acid in acute promyelocytic leukaemia.

Dr Seymour talks to ecancertv at EHA 2014 about a new oral drug, ABT-199/GDC-0199, which was designed to exclusively mimic the binding of the “BH3” structural element of the BCL-2 protein in CLL, to restore the regulatory process that tells cancer cells to self-destruct.

Dr Galetto talks to ecancertv at EHA 2014 about the genetic modification of T cells for fighting haematological cancers.